The 34 most recent market catalysts affecting $BSX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65
Oppenheimer analyst Suraj Kalia has adjusted the price target for Boston Scientific (BSX) from $85 to $65. This change reflects a revised valuation model or updated outlook from th…
Sep 17, 2026
Market Technicals
Bearish
Impact 55
Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50
Citigroup's downgrade of Boston Scientific from 'Buy' to 'Neutral' and the reduction of its price target from $57 to $50 signals a more cautious outlook on the company's stock. Thi…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Alpha Buying: 4 Falling Knives Insiders Are Buying
The filing details substantial insider purchases at Boston Scientific, Cardinal Infrastructure Group, GBank Financial Holdings, and Amrize, all of which have experienced significan…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific disclosed that a cyberattack in August disrupted global operations, impacting its ability to manufacture, process, and ship orders. This has led the company to an…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.
The headline indicates a significant corporate catalyst for Boston Scientific (BSX) due to a cybersecurity incident impacting its financial guidance. The 'sympathy' trading lower i…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific shares are trading lower after the company disclosed that it's unlikely to meet its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.
The cybersecurity incident at Boston Scientific (BSX) is a direct and significant negative catalyst, forcing the company to lower its financial guidance. This immediately impacts i…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific Discloses Its Unlikely To Meet Its FY26 And Q3 Adj EPS And Net Sales Growth Guidance After Cybersecurity Incident
Boston Scientific (BSX) has revealed that a cybersecurity incident, previously disclosed on August 26, 2026, will materially impact its Q3 and full-year 2026 financial performance.…
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 65
Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific has initiated a Class I recall of its Infinion CX Lead, a critical component in its Spinal Cord Stimulator System, due to mechanical stress causing fractures and …
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific shares are trading lower after the FDA disclosed it is aware that the companyissued a letter to affected customers recommending all unused Infinion CX Leads be removed from where they are used or sold.
The FDA's disclosure about Boston Scientific's recommendation to remove Infinion CX Leads is a significant negative catalyst for the company. This product recall directly impacts B…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads
Boston Scientific is facing a significant product safety issue with its Infinion CX leads, leading to 1,081 reported serious injuries. The FDA's awareness and Boston Scientific's r…
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 75
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Boston Scientific (BSX) disclosed a cybersecurity incident that has led to global operational disruptions, specifically impacting order processing and shipping. This is a significa…
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 75
Boston Scientific shares are trading lower after the company disclosed that it identified a cybersecurity incident affecting certain of its information technology systems that disrupted its operations.
This headline represents a significant corporate catalyst for Boston Scientific, directly impacting its share price negatively due to operational disruptions and the potential cost…
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 75
Boston Scientific Discloses Cybersecurity Threat Resulting In Disruption To Global Operations Including Order Processing And Shipping; Investigation Is Ongoing
Boston Scientific (BSX) has disclosed a significant cybersecurity incident that has disrupted its global operations, including critical functions like order processing and shipping…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Boston Scientific shares are trading higher after a Form 4 filing indicated that the CEO bought 186,240 shares at an average price of $48.33 per share.
The CEO's purchase of a substantial number of shares at a specific price indicates a strong belief in the company's intrinsic value and future performance. This insider buying ofte…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Boston Scientific CEO Mahoney Purchased 186,240 Shares @Avg Price Of $48.33/Share As Reported In Form 4 Filing
The purchase of 186,240 shares by CEO Mahoney at an average price of $48.33 is a strong vote of confidence from an insider who has intimate knowledge of the company's operations an…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Buy on Boston Scientific, Lowers Price Target to $67
UBS analyst Patrick Wood maintained a 'Buy' rating on Boston Scientific but lowered the price target from $74 to $67. This action suggests that while UBS still sees long-term value…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $70
RBC Capital analyst Kendall Au maintained an 'Outperform' rating on Boston Scientific (BSX) but significantly lowered the price target from $85 to $70. This action signals that whi…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $57
Truist Securities analyst Richard Newitter maintained a 'Buy' rating on Boston Scientific (BSX) but lowered the price target from $62 to $57. This action suggests that while the an…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
Evercore ISI Group Maintains Outperform on Boston Scientific, Lowers Price Target to $55
Evercore ISI Group analyst Vijay Kumar reaffirmed an 'Outperform' rating for Boston Scientific (BSX) but significantly lowered the price target from $65 to $55. This action signals…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
BSX stock has given up its prior loss. Boston Scientific shares were trading lower after the company reported Q2 financial results and lowered its FY26 adjusted EPS and sales guidance below estimates.
This headline highlights a significant corporate catalyst for Boston Scientific. The initial negative reaction to lowered long-term guidance (FY26 adjusted EPS and sales) suggests …
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific Cuts Forecast on Product Slowdown and Competition
Boston Scientific (BSX) reported Q2 results that beat consensus estimates, but the positive news was overshadowed by a significant cut to its fiscal 2026 sales and earnings guidanc…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
BSX stock has given up its prior gain. Boston Scientific shares were trading higher after the company reported better-than-expected Q2 financial results.
The headline highlights a significant corporate catalyst – better-than-expected earnings for Boston Scientific. However, the subsequent loss of gains suggests that the positive new…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific shares are trading lower after the company reported Q2 financial results and lowered its FY26 adjusted EPS and sales guidance below estimates.
The headline indicates a significant negative corporate catalyst for Boston Scientific (BSX). Lowered guidance for FY26 adjusted EPS and sales, coupled with a Q2 miss, directly imp…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Boston Scientific shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Boston Scientific (BSX), directly impacting its stock price positively due to strong financial performance. Better-tha…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 85
Boston Scientific Sees Q3 Adj EPS $0.80-$0.82 vs $0.83 Est; Sees Sales $5.217B-$5.318B vs $5.358B Est
Boston Scientific (BSX) announced Q3 adjusted EPS guidance of $0.80-$0.82, below the $0.83 analyst estimate, and sales guidance of $5.217B-$5.318B, also below the $5.358B estimate.…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 Est; Lowers FY2026 Sales Guidance from $21.479B-$21.780B to $21.178B-$21.379B vs $21.562B Est
Boston Scientific (BSX) has issued a significant downward revision to its fiscal year 2026 adjusted EPS and sales guidance. This move is a direct indication that the company expect…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Boston Scientific Q2 Adj. EPS $0.86 Beats $0.83 Estimate, Sales $5.442B Beat $5.361B Estimate
Boston Scientific announced Q2 adjusted EPS of $0.86, beating the $0.83 estimate by 3.61%, and sales of $5.442 billion, surpassing the $5.361 billion estimate by 1.52%. These resul…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
Boston Scientific Approves 2026 Global Restructuring Program; Plan Intends To Cut Headcount; Expects ~$700M - $800M As Pre-Tax Charges; Plan Expected To Reduce Annual Pre-Tax Expenses by $500M
Boston Scientific (BSX) has announced a significant global restructuring program, expected to incur pre-tax charges of $700M-$800M through 2026, largely due to headcount reductions…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 65
'Boston Scientific Gets $42 Million Stent Patent Verdict Reversed' - Bloomberg
Boston Scientific (BSX) has secured a significant legal victory, with an appeals court reversing a $42 million patent infringement verdict. This decision eliminates a substantial f…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $85
Oppenheimer analyst Suraj Kalia maintained an 'Outperform' rating on Boston Scientific, signaling continued confidence in the company's fundamentals and long-term growth prospects.…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $62
Truist Securities analyst Richard Newitter has updated his valuation for Boston Scientific, reducing the price target from $64 to $62. Despite this reduction, the 'Buy' rating is m…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 65
Mizuho Maintains Outperform on Boston Scientific, Lowers Price Target to $70
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Boston Scientific (BSX), signaling continued confidence in the company's long-term prospects. However, the signi…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $85
RBC Capital's analyst Shagun Singh reiterated an 'Outperform' rating for Boston Scientific (BSX) but significantly reduced the price target from $100 to $85. This action indicates …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.